Navigation Links
Mylan Announces Final FDA Approval for Fluoxetine Capsules

Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 40 mg.

Fluoxetine Capsules are the generic version of Eli Lilly and Company's Prozac(R) Capsules. Fluoxetine Capsules had U.S. sales of approximately $118 million for the 12 months ending March 31, 2007, for the 40 mg strength.

This product will be shipped immediately.

Mylan previously received approval and is currently marketing the 10 mg and 20 mg strength of fluoxetine capsules.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.


'"/>




Page: 1

Related medicine news :

1. Mylan Announces Tentative FDA Approval for Its ANDA
2. Mylan Wins Its Amlodipine Case With Pfizer
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. Indian PM Announces Of Setting Up India Study Center At Tashkent
7. PowderMed Announces Needle-Less Flu Vaccine
8. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
9. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care

Post Your Comments:
(Date:12/2/2009)... , BOSTON, Dec. 2 The Washingt... rises 8%. According to Coremetrics, a marketing ...cent on Cyber Monday compared to Cyber Monday 2008...la Sante Day Spas who reported today "Cyber Monda...et sales rose 59%" - said Tiffany Amorosino, COO o...
(Date:12/2/2009)...ving angioplasty within 90 minutes of hospital arr...(HealthDay News) -- A nationwide program to get fa...d of heart attack has dramatically reduced the tim...sty. , More than three-quarters of people with ...ectrocardiogram pattern that shows major blockage ...
(Date:12/2/2009)...drug used, the greater the sleep disturbances, stu...y News) -- The widely used club drug ecstasy appea...esearchers. , "People who use ecstasy need to k... immediate and dangerous problems such as sleep ap...pkins School of Medicine in Baltimore, said in a n...
(Date:12/2/2009)...nt prolongs life remains unclear, researchers say ...- New research suggests that enzyme replacement th...people with Fabry disease, a rare illness that aff...essive disease, linked to the lack of an enzyme th...can be fatal because it boosts the risk for a stro...
(Date:12/2/2009)...DENA, Calif., Dec. 2 Hu...ceived the Gold Seal of Approval from the Joint Co...e center. This means Huntington will join the net...out Los Angeles County. ,, "This is a signifi...t, a wonderful benefit for Pasadena and its surrou...
Breaking Medicine News(10 mins):Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 2Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 3Health News:Heart Attack Treatment Speeds Up Nationwide 2Health News:Heart Attack Treatment Speeds Up Nationwide 3Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2
.... (Nasdaq: CLRT ), a premier anatomic pathology...logists, oncologists and the pharmaceutical indust...009, the Company has renewed, expanded and extende...urrent market environment, having a solid investor...
...are, a leading software engineering and software t...d the availability of their third Software Technic...wnload Report The Software Technical Report offer...uality assurance tools and when to use automated v...
... is accepting entries for the 2009 HealthLeaders M.... Campaigns launched during 2008 are eligible and ... Marblehead, MA (PRWEB) March 3,...ed during 2008 are eligible and may be submitted i...
...m, The Flag Company, Inc.,s new ,Feel Good, Light ...sitive sentiments and lift spirits during this try...RWEB) March 3, 2009 -- In light of the frustrating...tive. Perfect for waiting rooms and office buildi...
...the KK Women,s and Children,s Hospital (KKH) can n...ry that allows them to undergo an anesthetic-free ...roids. , Singapore (PRWEB...lows them to undergo an anesthetic-free yet almost...
...hannel releases the first in a series of resident...ion with The Carpet and Rug Institute . , ...09 -- Before spending hundreds of dollars on one o... effort to provide consumers the information they ...
Other Medicine News:Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 2Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 3Health News:Clarient Renews and Expands Mezzanine Credit Facility With Safeguard 4Health News:For Medical Device Makers, Full Spectrum Software Releases New Software Technical Report, QA Software Automation and Software Testing 2Health News:Entry Period Opens for the 2009 HealthLeaders Media Marketing Awards Program with 11 New Categories 2Health News:Entry Period Opens for the 2009 HealthLeaders Media Marketing Awards Program with 11 New Categories 3Health News:The Flag Company, Inc. Releases 'Feel Good' Light Lenses to Help Counter Gloomy Economic Outlook 2Health News:The Flag Company, Inc. Releases 'Feel Good' Light Lenses to Help Counter Gloomy Economic Outlook 3Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 2Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 3Health News:Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids 4Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 2Health News:Shopping for a Vacuum Cleaner? Know What You're Buying! Internet Site and Rating System Can Help 3
(Date:12/2/2009)... , ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall... favorable initial results from the first stage of... safety and immunogenicity of the company,s 2009 H...accine. Novavax is conducting this study in colla...port registration of the vaccine in Mexico and pot...
(Date:12/2/2009)... , NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -...today announced that the U.S. Food and Drug Admini...for KRX-0401 (perifosine), the Company,s novel, po...hat inhibits the phosphoinositide 3-kinase (PI3K)/...ory multiple myeloma. ,, The Fast Track progr...
(Date:12/2/2009)... , BIRMINGHAM, Ala., Dec. 2 A... diagnosed with cancer. For adults 65 and over, th...the odds of a man developing prostate cancer are o...ncer are one in nine. Vision loss threatens the o...sk of injuries, depression and inability to comple...
Breaking Medicine Technology:NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 2Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 3Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma 4Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2HMS Holdings Corp Hosts Second Quarter 2009 Financial Teleconference and Presentation 51790 1HMS Holdings Corp Hosts Second Quarter 2009 Financial Teleconference and Presentation 51790 2Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast 51787 1Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast 51787 2New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 1New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 2New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 3New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 4
... a powerful predictor of eventual treatment ... Roche today announced final results from,the REP...once-weekly,PEGASYS(R) (peginterferon alfa-2a) and...romising treatment option for patients whose infec...other pegylated interferon (Peg-,Intron(R), pegint...
...DM Pharma, Inc.,(Nasdaq: IDMI ) today announced u...lanoma vaccine clinical trial (DC-MEL-202). The up...t UVIDEM showed evidence of clinical,activity and ...d in,patients with advanced melanoma. The data ar...nternational Society for Biological Therapy of Can...
Other Medicine Technology:Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 2Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 3Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 4Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 5Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 6Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin 7IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 2IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 3IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients 4
Eclipse TS100
Surgical Drill Bits
...vised charts incorporate the slight change in the ...derived from the best corrected visual acuity exam...original charts difficulty scores were derived fro...revised arrangement of letters which resulted in t...
Stereo Fly Test
Medicine Products: